BGM Group announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited to acquire 100% of Wonder Dragon’s equity interests by issuing 38,165,290 Class A ordinary shares for $2 per share, for a total deal valuation of ¥ $550 million. The deal is expected to be completed in the Q2 of 2025.
Wonder Dragon has over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. And these premium tea products, known for their medicinal and collectible historical value, provide a solid foundation for BGM Group’s research and development efforts.
This deal enhances BGM Group’s position in the healthcare sector by expanding its health product portfolio and market reach. And the company has been at the forefront of integrating AI technology, big data analytics, and biopharmaceutical innovations to modernize traditional industries.
Following the deal, BGM Group plans to optimize tea production efficiency, enhance product adaptability, and accelerate the development of active ingredients for medicinal applications using its AI-based decision-making platform.
KEY QUOTE:
“Wonder Dragon’s Qingzhuan dark tea resources, combined with our biotechnology platform, will significantly advance our medicinal tea product development and distribution. By leveraging our technological expertise, we intend to introduce new health-focused tea products like ginseng Qingzhuan dark tea and goji berry Qingzhuan dark tea, further diversifying our ‘medicine + tea + health’ product ecosystem.”
– Xin Chen, CEO of BGM Group
